Catalyst Pharma Has Top-Line Results of CMS-001, a Phase 3 Trial of Firdapse

CMS-001 trial is the first and only double-blinded, placebo-controlled study ever conducted in genetically confirmed CMS patients

Results in full population across all tested subtypes of CMS did not achieve statistical significance for the primary or secondary endpoints

MuSK-Myasthenia Gravis Phase 3 trial and SMA Type-3 proof of concept study both remain on schedule

https://www.marketscreener.com/CATALYST-PHARMACEUTICALS-36303/news/Catalyst-Pharmaceuticals-Announces-Top-Line-Results-of-CMS-001-a-Phase-3-Trial-of-Firdapse-Amifam-29480543/